Short bowel syndrome patients can absorb almost nothing without lifelong IV nutrition. The innovative drug teduglutide entered China through Lecheng's 'first-track' channel — its first mainland patient was a toddler, and by spring 2025 the path that started in Lecheng had reached 25 families. The drug has now been formally approved for the whole country.
短肠综合征患者没有静脉营养几乎无法吸收。创新药替度格鲁肽经乐城“先行先试”通道进入中国——中国大陆首位治疗者是1岁多的患儿；到2025年春，这条从乐城出发的路已惠及25个家庭。如今该药已正式获批上市。
This page is a short English/Chinese summary of the facts in a patient story published by the Lecheng Administration. Photos are from that publication, credited; a link to the original Chinese article sits at the foot of this page. 本页是对Lecheng Administration发布的一篇患者故事中事实的简短中英摘要。照片取自该发布并标注来源；官方中文原文链接见本页页脚。
